Table 1. Parameters for base-case analysis, one-way DSA and PSA.
| Parameters | Base case | Range for DSA | Parameters (or distribution) for PSA* | Reference | |
|---|---|---|---|---|---|
| Cost ($) | |||||
| Pembrolizumab/mg | 25.50 | 20.41–30.61 | Fixed | (20) | |
| Docetaxel/mg | 10.6 | 8.5–12.7 | Gamma | (20) | |
| PD-L1 test | 48.5 | 38.8–52.2 | Normal | (24) | |
| Routine follow-up per cycle | 55.6 | 41.7–69.4 | Log-normal | (25) | |
| Subsequent systemic therapy in PP state per cycle | 854.1 | 706.5–992.4 | Log-normal | (26) | |
| Best supportive care per cycle | 337.5 | 158.7–793.7 | Log-normal | (25) | |
| Terminal phase cost | 2627.8 | 2,291.8–2,966.6 | Log-normal | (26) | |
| Neutropenia per event | 461.5 | 415.4–507.7 | Log-normal | (27) | |
| Fatigue per event | 115.4 | 103.8–126.9 | Log-normal | (27) | |
| Diarrhea | 150 | 100–200 | Log-normal | Local charge | |
| Severe skin reaction | 248 | 200–296 | Log-normal | Local charge | |
| Pneumonitis | 200 | 100–300 | Log-normal | Assumption | |
| Utility | |||||
| PFS | 0.804 | 0.643–0.881 | Beta | (19) | |
| PP | 0.321 | 0.257–0.385 | Beta | (19) | |
| Disutility | Beta | ||||
| Severe skin reaction | 0.30 | 0.10–0.40 | Beta | Assumption | |
| Fatigue | 0.07 | 0.07–0.49 | Beta | (19) | |
| Neutropenia | 0.20 | 0.15–0.50 | Beta | (19) | |
| Diarrhea | 0.07 | 0.06–0.35 | Beta | (19) | |
| Pneumonitis | 0.20 | 0.1–0.3 | Beta | Assumption | |
| Duration of adverse events (weeks) | |||||
| Severe skin reaction | 1 | Fixed | Fixed | Assumption | |
| Fatigue | 1 | Fixed | Fixed | Assumption | |
| Neutropenia | 1 | Fixed | Fixed | Assumption | |
| Diarrhea | 1 | Fixed | Fixed | Assumption | |
| Pneumonitis | 1 | Fixed | Fixed | Assumption | |
| Patient weight (kg) | 65 | Fixed | Fixed | (25) | |
*, the simulated parameters for probabilistic sensitivity analysis were set with the standard error at 20% of the base-case value. DSA, deterministic sensitivity analyses; PSA, probabilistic sensitivity analysis.